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A B S T R A C T
Purpose: Almost all antipsychotics have been associated with a risk of epileptic seizure provocation.
Among the ﬁrst-generation antipsychotics (FGA) chlorpromazine appears to be associated with the
greatest risk of seizures among the second-generation antipsychotics (SGA) clozapine is thought to be
most likely to cause convulsions. This information is largely based on studies that are not sufﬁciently
controlled. Besides, information about the seizure risk associated with newer antipsychotics is scarce.
Method: The Pharmacovigilance Unit of the Basque Country (network of centers of the Spanish
Pharmacovigilance System, SEFV) provided reporting data for adverse reactions (AR) from the whole
SEFV to estimate the reporting odds ratio (ROR) for antipsychotics and seizures (‘‘convulsions’’ as Single
MedDra Query). Data was obtained from SEFV database from 1984 to the June 2011.
Results: The total number of convulsions reported for SGA was 169 (total reported AR 3.204). The
number of convulsions reported for FGA was 35 (total reported AR 2.051). 94 convulsions were reported
in association with clozapine (total AR 1.052). The ROR for SGA versus FGA was 3.2 (CI 95%: 2.21–4.63).
The ROR for SGA excluding clozapine versus FGA was 2.08 (CI 95%: 1.39–3.12).
Conclusion: Our results show that SGA may pose a higher risk of seizures than FGA, mainly, but not only
due to clozapine. This is line with recent studies suggesting that some SGA carried a higher average risk
of electroencephalographic abnormalities than many FGA. Nonetheless, It is well known that
spontaneous reports do not allow strong inferences about adverse drug effects, because differences
in reporting fractions by time, drug or type of event are difﬁcult or even impossible to distinguish from
differences in the occurrence rates of adverse events. Still, we consider that the possibility of SGA
carrying a higher risk of seizure induction than FGA warrants further research.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Almost all ﬁrst- and second-generation antipsychotic drugs
have been implicated in increasing the risk of epileptic seizures.1
Antipsychotics are used for a wide range of conditions and may be
indicated in people with epilepsy. In fact, several cross-sectional
studies have demonstrated that psychotic disorder and other
psychiatric conditions for which antipsychotics may be prescribed
are more common among people with epilepsy than in the general
population.2 Indeed, it has been estimated that the overall
prevalence of psychiatric disorders in patients with epilepsy is
as high as 25% (psychosis affects 2–9% of patients) – and even
higher in pharmocoresistant cases seen in specialized centers.3* Corresponding author. Tel.: +34 945 00 65 33; fax: +34 945 00 65 87.
E-mail address: Unax.lertxundietxebarria@osakidetza.net (U. Lertxundi).
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http://dx.doi.org/10.1016/j.seizure.2012.10.009Low starting doses, use of minimum effective doses and
avoidance of unnecessary antipsychotic polypharmacy have been
described as strategies which may lower the risk of seizure
provocation associated with these drugs.4
Previous studies demonstrate that clozapine is associated with
a clear, dose-dependent risk of seizure provocation and compared
to other second-generation antipsychotics, appears to have the
highest risk of seizure induction.5 Among ﬁrst-generation anti-
psychotics, chlorpromazine seems to be associated with the
greatest risk of provoking epileptic seizures. Risperidone, ﬂuphen-
azine, haloperidol, molindone, pimozide and triﬂuoperazine seem
to be the least likely antipsychotics to induce seizures.1 Data about
newer antipsychotics, such as aripiprazole, paliperidone and
ziprasidone are scarce.6–7 As it was temporally withdrawn from
the market, data about sertindole are also scant.8Whether second-
generation antipsychotics are safer than ﬁrst-generation anti-
psychotics in terms of seizure induction is not known.vier Ltd. All rights reserved.
Table 1
Reports of suspected drug-related seizures in FEDRA database, 1984–June 2011.
First generation
antipsychotics (FGA)
Total number of
adverse reports
Total number
of convulsions
Chlorpromazine 101 4
Clotiapine 96 5
Fluphenazine 82 4
Haloperidol 465 5
Levomepromazine 186 4
Loxapin 3 0
Periciazine 20 0
Perphenazine 72 3
Pimozide 29 1
Pipothiazine 4 0
Sulpiride 668 4
Thioridazine 145 3
Tiapride 55 0
Tioproperazine 6 1
Triﬂuoperazine 39 1
Zuclopentixole 80 0
Total 2051 35
Second generation
antipsychotics (SGA)
Total number of
adverse reports
Total number
of convulsions
Amisulpride 51 0
Aripiprazole 168 6
Clozapine 1052 94
Olanzapine 471 21
Paliperidone 77 1
Quetiapine 276 19
Risperidone 962 18
Sertindole 18 0
Ziprasidone 129 10
Total 3204 169
Table 4
Reporting odds ratio (ROR) for antipsychotics and seizures in VigiBase.
Reported
convulsions
Total reported
adverse reactions
Second generation antipsychotics (SGA) 5.412 80.300
First generation antipsychotics (FGA) 1.225 36.057
ROR for SGA vs. FGA: 2.03 (1.90–2.16)
Table 2
Reporting odds ratio (ROR) for antipsychotics and seizures in FEDRA.
ROR CI 95%
SGAa vs. FGAb 3.2 2.21–4.63
SGA excluding clozapine vs. FGA 2.08 1.39–3.12
Clozapine + olanzapine + quetiapine vs. other SGA 4.65 3.19–6.80
a Second generation antipsychotic.
b First generation antipsychotic.
Table 3
Reporting odds ratio (ROR) for antipsychotics and seizures in Eudravigilance.
Reported
convulsions
Total reported
adverse reactions
Second generation antipsychotics (SGA) 3.009 50.615
First generation antipsychotics (FGA) 402 9.025
ROR for SGA vs. FGA: 1.33 (1.20–1.48)
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the seizure threshold is based on studies that are not sufﬁciently
controlled and typically report patients with other risk factors for
seizures. Case reports, often complicated by polypharmacy and
other risk factors for seizures, form a substantial portion of the
available literature.
In order to ﬁnd out if different antipsychotic drugs are
associated with different risks of causing epileptic seizures, we
studied data about antipsychotic-related epileptic seizures drawn
from spontaneous reports to several Spanish and international
pharmacovigilance databases.
2. Methods
2.1. Case/non-case method
The case/non-case method measures the disproportionality of
combinations of a drug and a particular adverse drug report (ADR) in
a pharmacovigilance database.9 This method can be used to generate
safety signals. Cases are deﬁned as reports of the ADR of interest and
non-cases as all other reports of ADR. For each drug of interest, the
association with the ADR was assessed by calculating an ADR
reporting odds ratio (ROR) with its 95% conﬁdence interval (CI).
2.2. Selection of cases and non-cases
Since 1984, all ADR reports sent spontaneously by health
professionals have been entered into the Spanish Pharmacovigi-
lance FEDRA database. The Pharmacovigilance Unit of the Basque
Country (network of centers of the Spanish Pharmacovigilance
System, SEFV) provided reporting data from the whole SEFV
between 1984 and June 23rd, 2011 to estimate the reporting odds
ratio (ROR). To identify cases of epileptic seizures we utilized the
Standardized MedDRA Query (SMQ) ‘‘Convulsions’’. SMQs are
groupings of MedDRA terms, ordinarily at the preferred term level
that relate to a deﬁned medical condition or area of interest. This
study relies on MedDRA version 14.1. Non-cases, used as controls,
were all the remaining ADR reports recorded in the database
during the same period. Drug exposition was deﬁned by the
presence in the report of the drug checked ‘‘suspect’’ according to
the WHO (World Health Organization) criteria whatever the level
of causality assessment. Subsequently, data from the European
Pharmacovigilance database (Eudravigilance) and WHO Pharma-
covigilance database (VigiBase) were also consulted for a
conﬁrmatory analysis.
2.3. Statistical analysis
Collected data were compared between reports deﬁned as
convulsions (cases) and all other reports in the database (non-
cases). We calculated a reporting odds ratio (ROR) to compare risk
of exposure to different drugs in cases and non-cases. RORs were
given with their 95% conﬁdence interval.
3. Results
Reports of suspected drug-related seizures and total number of
adverse reports in FEDRA database are shown in Table 1.
Reporting odds ratio calculated from the data of Table 1 are
shown in Table 2.
3.1. Data analysis from Eudravigilance and VigiBase: conﬁrmatory
analysis
Reporting odds ratio for antipsychotics and seizures in
Eudravigilance (from 1984 to June 2011) are shown in Table 3.Reporting odds ratio for antipsychotics and seizures in the WHO
Pharmacovigilance database10 (1968-February 2006) are shown in
Table 4.
4. Discussion
We found that spontaneous seizure reports for second-genera-
tion antipsychotics are more frequent than for ﬁrst-generation
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Olanzapine and quetiapine, both chemically related to clozapine,
may carry a higher risk than expected.
Interestingly, our results are in line with one study carried out
in 323 hospitalized patients which found that some atypical
antipsychotics present a higher average risk of electroencephalo-
graphic (EEG) abnormalities than many typical neuroleptics.11 The
risk was greatest with clozapine and unexpectedly high with
olanzapine, while risperidone was similar to standard high-
potency neuroleptics. Quetiapine had a very low rate of EEG
abnormality risk among the very few subjects who received this
agent. Another study found that EEG changes were common with
olanzapine doses of >20 mg.12
Although other variables such as dose, age, indication for which
the antipsychotic was being used were not taken into account, the
fact that the analysis of all three databases yielded similar results
strengthens our conclusions.
On the other hand, several epidemiologic studies have found
that psychiatric disease (including depression, anxiety disorders,
bipolar disorder, and psychoses) is more frequent among people
with epilepsy than in the general population.2,3 Thus, a deeper
understating of the epileptogenic risk of individual antipsychotics
is urgently needed.
4.1. Limitations
The case/non-case method can be a very useful method for
assessing and detecting associations between a speciﬁc adverse
drug effect and drug exposure in real conditions of use, because
it is simple, quick and used data are already available.
Nevertheless, it is important to recall that these dispropor-
tionality studies should only be considered as exploratory in
the context of signal detection, as they do not allow
quantiﬁcation of the true risk. Indeed, differences in reporting
fractions by time, drug or type of event are difﬁcult or
impossible to distinguish from differences in the occurrence
rates of adverse events making make inferences from such data
problematic.135. Conclusions
Our ﬁndings suggest that second-generation antipsychotics
may carry a greater epileptogenic risk than ﬁrst-generation
antipsychotics, especially but not only due to clozapine. Olanza-
pine and quetiapine, both chemically related to clozapine, may
carry a higher risk than expected. Thus, a cautious approach seems
advisable when prescribing these drugs to patients with known
risk factors for a lowered seizure threshold, including the
combination with other drugs causing potential pharmacokinetic
and/or pharmacodynamic interactions.
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